Estrella Immunopharma annual stock-based compensation
2022
2023
2024
2024
2025
Estrella Immunopharma Stock-Based Compensation Growth & History (ESLA)
Estrella Immunopharma's stock-based compensation was $618,974 for fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $618,974 | $186,718 | +43.20% |
| 2024 · Dec 31 | 2024-12-31 | $432,256 | — | — |
| 2024 · Jun 30 | 2024-06-30 | $1.2M | $785,058 | +191.67% |
| 2023 | 2023-06-30 | $409,595 | $279,627 | +215.15% |
| 2022 | 2022-06-30 | $129,968 | — | — |
Estrella Immunopharma quarterly stock-based compensation
Q3.22
Q4.22
Q1.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $145,298 | −$13,800 | −8.67% |
| Q1 2026 | 2026-03-31 | $146,714 | −$12,381 | −7.78% |
| Q4 2025 | 2025-12-31 | $148,360 | — | — |
| Q3 2025 | 2025-09-30 | $152,421 | $152,421 | — |
| Q2 2025 | 2025-06-30 | $159,098 | $159,098 | — |
| Q1 2025 · Mar 31 | 2025-03-31 | $159,095 | $159,095 | — |
| Q1 2025 · Sep 30 | 2024-09-30 | $0 | −$1.2M | — |
| Q4 2024 | 2024-06-30 | $0 | −$102,398 | — |
| Q3 2024 | 2024-03-31 | $0 | −$102,399 | — |
| Q2 2024 | 2023-12-31 | $0 | −$102,399 | — |
| Q1 2024 | 2023-09-30 | $1.2M | $1.1M | +1066.66% |
| Q4 2023 | 2023-06-30 | $102,398 | — | — |
| Q1 2023 | 2023-03-31 | $102,399 | — | — |
| Q4 2022 | 2022-12-31 | $102,399 | — | — |
| Q3 2022 | 2022-09-30 | $102,399 | — | — |
Estrella Immunopharma stock-based compensation trends
Between the periods ended 2022-06-30 and 2025-12-31, Estrella Immunopharma's stock-based compensation increased from $129,968 to $618,974, a change of $489,006. The latest reported quarter, Q2 2026, shows $145,298.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗